LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
Series of manufacturing disasters highlights importance of partner due diligence in China
Chinese CMOs with a proven track record in quality will be able to differentiate themselves amidst the series of manufacturing problems this year, and the ongoing US-China trade war, says GlobalData

The recent pharma regulatory reforms by China are expected to provide opportunities for both domestic as well as foreign contract manufacturing organisations (CMOs).

A series of recent manufacturing scandals highlights the importance of performing due diligence when picking a pharma manufacturing partner in the country, says data and analytics company GlobalData.

In July, the European Medicines Agency discovered N-nitrosodimethylamine, a probable carcinogen, in batches of the drug valsartan, which is used to treat high blood pressure and heart failure, manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd.

The problem was much larger than originally thought as soon after, the same contaminant was discovered in valsartan made by another CMO, Zhejiang Tianyu Pharmaceutical Co Ltd. Regulators then found a second impurity, N-Nitrosodiethylamine, in many valsartan batches.

Fiona Barry, associate editor of GlobalData’s PharmSource said, “Unlike many of the other manufacturing problems in China this summer, the CMOs involved in the valsartan production did little wrong. The impurity arose because of changes in the way the active substance was manufactured, but these changes had been approved by regulators which also missed the problem.”

Since the discovery of the problem, regulators have developed two methods to detect the impurities in valsartan drug products—a chromatography-tandem mass spectrometry (GC-MS/MS) method utilising liquid injection and a combined gas chromatography-mass spectrometry (GC/MS) headspace method.

Separate scandals have also hit other Chinese pharma manufacturers. Most recently, Changchun Changsheng Life Sciences Ltd. was fined following an investigation into its illegal production of human rabies vaccine. The controversy and spot checks prompted by the Changsheng scandal have caught out other Chinese pharma manufacturers.

Anonymous whistle-blowers claiming to be employees of Chongqing Pharmaceutical Research Institute, a generic API and development services subsidiary of Shanghai Fosun Pharmaceutical Group Co. Ltd., accused the company of using unapproved processes and using fraudulent records to apply for GMP certification of a new production facility in Chongqing’s Changshou district.

With its reputation at stake, China has been attempting to overhaul its regulatory process with a series of rapid policy changes. In September 2018, China restructured its medicines regulator from China Food and Drug Administration (CFDA) to National Medical Products Administration (NMPA).

Barry concludes: “The manufacturing problems experienced this year, and the ongoing US-China trade war means China requires careful consideration as a partner. Chinese CMOs with a proven track record in quality and in partnering with foreign companies, or even with their own footprint in the US or EU, will be able to differentiate themselves.”

Source: GlobalData

Click here for the complete issue.

news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
Asia Pacific Biotech News

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management - Technologies for biotech and pharmaceutical industries
Regenerative technology - Meat of the future
Doctor Robot - The digital healthcare revolution
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy